Skip to main content

Advertisement

Table 1 Patients and treatment characteristics for the two groups

From: Can advanced new radiation therapy technologies improve outcome of high grade glioma (HGG) patients? analysis of 3D-conformal radiotherapy (3DCRT) versus volumetric-modulated arc therapy (VMAT) in patients treated with surgery, concomitant and adjuvant chemo-radiotherapy

  3DCRT VMAT
  Number Percent Number Percent
Total 167 49 174 51
Gender
 Female 57 34 67 38.5
 Male 110 66 107 61.5
Median Age 53 yrs (range 20–82 yrs) 54 yrs (range 19–82 yrs)
Karnosky Performance Status (KPS)
 60 6 3 3 2
 70 26 16 25 14
 80 68 41 52 30
 90 44 26 52 30
 100 23 14 42 24
Histology
 Glioblastoma (GBM) 129 77 122 70
 Anaplastic Astrocytoma (AA) 20 12 29 17
 Anaplastic Oligoastrocytoma (AOA) 9 5.5 10 6
 Anaplastic Oligodendroglioma (AO) 9 5.5 13 7
Isocitrate dehydrogenase (IDH) mutation status
 Wild type 126 72
 Mutated 38 22
 NA (not available) 167 100 10 6
1p19q codelation
 Codeleted 18 11 30 17
 Non codeleted 20 12 22 13
 NE (not evaluated for GBM pts) 129 77 122 70
O-6-methylguanine-DNA-methyltransferase (MGMT) promoter methylation status
 Methylated 94 54 107 61
 Unmethylated 76 46 67 49
Surgery
 Biopsy (B) 47 28 22 13
 Partial Resection (PR) 58 35 58 33
 Subtotal Resection (SR) 15 9 26 15
 Complete Resection (CR) 47 28 68 39
Adjuvant treatment
 RT + concomitant CHT+ adjuvant CHT (TMZ) 167 100 174 100
  1. Abbreviations: 3DCRT 3dimensional conformal radiotherapy, VMAT volumetric modulated arc therapy, RT radiotherapy, CHT chemotherapy, TMZ Temozolomide